DPLM:LSEDiploma PLC Analysis
Data as of 2026-06-18 - not real-time
£7,040.00
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Diploma PLC has posted a solid interim earnings beat, lifting analyst price targets to £73.90 and sending the stock up 4.5% to £70.25. The share price sits above its 20‑day SMA (≈ £6,977) and the 50‑day SMA (≈ £6,888), confirming a short‑term bullish bias, while the 200‑day SMA (≈ £5,818) remains well below current levels, underscoring a longer‑term uptrend.
However, valuation metrics raise caution: the trailing P/E of 49.9 far exceeds the industry average of 31.2 and the DCF‑derived fair value of £45.2 k, indicating the stock is currently overvalued. Technical momentum is mixed – RSI sits at a neutral 56, MACD shows a bearish histogram, and volume is decreasing, hinting at waning buying pressure. Fundamentals remain resilient with 16.8% revenue growth, a healthy gross margin of 47.5%, and a dividend yield of 0.9% supported by a 44% payout ratio. The low beta (~0.28) suggests limited market‑wide volatility, yet 30‑day price volatility of 26% and thin trading volumes point to liquidity concerns. Overall, the company’s diversified geographic footprint mitigates regional risk, but the high valuation and sector cyclicality temper enthusiasm. Investors should weigh the strong earnings momentum and dividend against the overvaluation and liquidity constraints when deciding on position sizing.
However, valuation metrics raise caution: the trailing P/E of 49.9 far exceeds the industry average of 31.2 and the DCF‑derived fair value of £45.2 k, indicating the stock is currently overvalued. Technical momentum is mixed – RSI sits at a neutral 56, MACD shows a bearish histogram, and volume is decreasing, hinting at waning buying pressure. Fundamentals remain resilient with 16.8% revenue growth, a healthy gross margin of 47.5%, and a dividend yield of 0.9% supported by a 44% payout ratio. The low beta (~0.28) suggests limited market‑wide volatility, yet 30‑day price volatility of 26% and thin trading volumes point to liquidity concerns. Overall, the company’s diversified geographic footprint mitigates regional risk, but the high valuation and sector cyclicality temper enthusiasm. Investors should weigh the strong earnings momentum and dividend against the overvaluation and liquidity constraints when deciding on position sizing.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Bullish price above short‑term moving averages
- Recent earnings beat and raised price target
- Support level at £6,700 offering downside cushion
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Strong revenue growth (16.8%) and expanding margins
- Attractive dividend yield with sustainable payout
- Forward P/E compression to 27.8 suggesting valuation improvement
Long Term
> 3 yearsNeutral
Model confidence: 6/10
Key Factors
- Current price well above DCF fair value
- High overall valuation relative to peers
- Sector cyclicality and elevated price volatility
Key Metrics & Analysis
Financial Health
Revenue Growth16.80%
Profit Margin11.50%
P/E Ratio49.9
ROE18.95%
ROA10.78%
Debt/Equity47.45
P/B Ratio9.0
Op. Cash Flow£283.9M
Free Cash Flow£244.3M
Industry P/E31.2
Technical Analysis
TrendBullish
RSI55.9
Support£6,700.00
Resistance£7,191.87
MA 20£6,976.99
MA 50£6,887.80
MA 200£5,817.87
MACDBearish
VolumeDecreasing
Fear & Greed Index88.5
Valuation
Fair Value£4,521.97
Target Price£7,703.75
Upside/Downside9.43%
GradeOvervalued
TypeGrowth
Dividend Yield0.90%
Risk Assessment
Beta0.28
Volatility26.44%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.